Vivos Therapeutics (VVOS) Accumulated Expenses (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Accumulated Expenses data on file, last reported at $6.1 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $6.1 million, up 744.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (up 744.34% YoY), and the FY2025 annual result was $6.0 million, up 168.04% from the prior year.
• Accumulated Expenses advanced to $6.1 million in Q1 2026 per VVOS's latest filing, from $6.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $6.1 million in Q1 2026 and troughed at $724000.0 in Q1 2025.
• A 5-year average of $2.3 million and a median of $1.9 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses plunged 70.64% in 2025, then jumped 744.34% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $1.9 million in 2022, then gained by 22.07% to $2.3 million in 2023, then declined by 4.28% to $2.2 million in 2024, then surged by 168.04% to $6.0 million in 2025, then advanced by 2.09% to $6.1 million in 2026.
• Business Quant data shows VVOS's Accumulated Expenses at $6.1 million in Q1 2026, $6.0 million in Q4 2025, and $1.2 million in Q3 2025.